Literature DB >> 18692341

Assessing the diagnostic importance of nonviable bacterial cells in respiratory infections.

Geraint B Rogers1, Franziska A Stressmann, Garrit Koller, Thomas Daniels, Mary P Carroll, Kenneth D Bruce.   

Abstract

Identification of bacteria in clinical samples is fundamental to combating infections. Modern molecular genetic approaches exploit nucleic acids signals from clinical samples. However, DNA-derived signals can originate from nonviable bacterial cells and, therefore, generate data that could be misinterpreted. Terminal restriction fragment length polymorphism profiling of cystic fibrosis sputum samples was combined with propidium monoazide (PMA) photo-induced cross-linking. PMA is highly membrane impermeant and is excluded from viable bacteria but readily penetrates dead cells. Exposure to a light source renders DNA in permeable cells incapable of contributing to polymerase chain reaction. PMA treatment was shown to effectively prevent dead bacteria, spiked into sputum samples, from contributing to profiles. Comparison of treated and untreated clinical samples indicated that dead bacterial cells significantly bias untreated profiles. These findings highlight the significant contribution that nonviable bacteria can make to DNA-based diagnostic analysis of clinical samples while providing a simple and effective means of avoiding such bias.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18692341     DOI: 10.1016/j.diagmicrobio.2008.06.011

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  29 in total

Review 1.  Next-generation sequencing in the analysis of human microbiota: essential considerations for clinical application.

Authors:  Geraint B Rogers; Kenneth D Bruce
Journal:  Mol Diagn Ther       Date:  2010-12-01       Impact factor: 4.074

2.  Comparing the microbiota of the cystic fibrosis lung and human gut.

Authors:  Geraint B Rogers; Mary P Carroll; Lucas R Hoffman; Alan W Walker; David A Fine; Kenneth D Bruce
Journal:  Gut Microbes       Date:  2010-01-29

3.  Changes in cystic fibrosis airway microbiota at pulmonary exacerbation.

Authors:  Lisa A Carmody; Jiangchao Zhao; Patrick D Schloss; Joseph F Petrosino; Susan Murray; Vincent B Young; Jun Z Li; John J LiPuma
Journal:  Ann Am Thorac Soc       Date:  2013-06

4.  Culture-Independent Detection of Nontuberculous Mycobacteria in Clinical Respiratory Samples.

Authors:  Gianny P Scoleri; Jocelyn M Choo; Lex E X Leong; Thomas R Goddard; Lisa Shephard; Lucy D Burr; Ivan Bastian; Rachel M Thomson; Geraint B Rogers
Journal:  J Clin Microbiol       Date:  2016-07-13       Impact factor: 5.948

5.  New perspectives on viable microbial communities in low-biomass cleanroom environments.

Authors:  Parag Vaishampayan; Alexander J Probst; Myron T La Duc; Emilee Bargoma; James N Benardini; Gary L Andersen; Kasthuri Venkateswaran
Journal:  ISME J       Date:  2012-10-11       Impact factor: 10.302

6.  Decade-long bacterial community dynamics in cystic fibrosis airways.

Authors:  Jiangchao Zhao; Patrick D Schloss; Linda M Kalikin; Lisa A Carmody; Bridget K Foster; Joseph F Petrosino; James D Cavalcoli; Donald R VanDevanter; Susan Murray; Jun Z Li; Vincent B Young; John J LiPuma
Journal:  Proc Natl Acad Sci U S A       Date:  2012-03-26       Impact factor: 11.205

Review 7.  Emerging pathogenic links between microbiota and the gut-lung axis.

Authors:  Kurtis F Budden; Shaan L Gellatly; David L A Wood; Matthew A Cooper; Mark Morrison; Philip Hugenholtz; Philip M Hansbro
Journal:  Nat Rev Microbiol       Date:  2016-10-03       Impact factor: 60.633

8.  Determining cystic fibrosis-affected lung microbiology: comparison of spontaneous and serially induced sputum samples by use of terminal restriction fragment length polymorphism profiling.

Authors:  Geraint B Rogers; Stuart Skelton; David J Serisier; Christopher J van der Gast; Kenneth D Bruce
Journal:  J Clin Microbiol       Date:  2009-11-11       Impact factor: 5.948

9.  Detection and Quantification of Viable and Nonviable Trypanosoma cruzi Parasites by a Propidium Monoazide Real-Time Polymerase Chain Reaction Assay.

Authors:  Beatriz Cancino-Faure; Roser Fisa; M Magdalena Alcover; Teresa Jimenez-Marco; Cristina Riera
Journal:  Am J Trop Med Hyg       Date:  2016-05-02       Impact factor: 2.345

Review 10.  Fluoroquinolones in the treatment of bronchopulmonary disease in cystic fibrosis.

Authors:  Matthew Hurley; Alan Smyth
Journal:  Ther Adv Respir Dis       Date:  2012-09-11       Impact factor: 4.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.